Literature DB >> 26368033

Use of the Impella 5.0 Device as a Bridge to Recovery in Adult Fulminant Viral Myocarditis.

Daniel J P Burns1, Mackenzie A Quantz.   

Abstract

We present a case of a 48-year-old female patient successfully bridged to recovery with the Impella 5.0 microaxial pump (Abiomed, Danvers, MA USA) after presenting with cardiogenic shock secondary to acute fulminant viral myocarditis. After 1 week of flu-like symptoms, the patient presented to her community emergency department with chest pain and hypotension. A diagnosis of inferior ST elevation myocardial infarction was made; subsequent angiography demonstrated normal coronary arteries and a left ventricular ejection fraction of 10%. A provisional diagnosis of viral myocarditis was made. As her condition deteriorated further, she underwent insertion of an Impella 5.0 after failure of supportive medical therapy. Myocardial recovery occurred, and the Impella was removed after 1 week. After a prolonged cardiac intensive care unit stay requiring temporary hemodialysis, the patient recovered sufficiently to tolerate device explant, transfer to the recovery ward, and ultimate discharge home. This case report highlights the benefit of mechanical circulatory support in a patient with cardiogenic shock from viral myocarditis as well as some of the complications that can occur in this critically ill subset of patients.

Entities:  

Mesh:

Year:  2015        PMID: 26368033     DOI: 10.1097/IMI.0000000000000171

Source DB:  PubMed          Journal:  Innovations (Phila)        ISSN: 1556-9845


  2 in total

1.  Effects of the MAPK pathway and the expression of CAR in a murine model of viral myocarditis.

Authors:  Ling Niu; Chunli Li; Zhenzhou Wang; Hui Xu; Xinjiang An
Journal:  Exp Ther Med       Date:  2016-11-18       Impact factor: 2.447

Review 2.  Chinese society of cardiology expert consensus statement on the diagnosis and treatment of adult fulminant myocarditis.

Authors:  Daowen Wang; Sheng Li; Jiangang Jiang; Jiangtao Yan; Chunxia Zhao; Yan Wang; Yexin Ma; Hesong Zeng; Xiaomei Guo; Hong Wang; Jiarong Tang; Houjuan Zuo; Li Lin; Guanglin Cui
Journal:  Sci China Life Sci       Date:  2018-12-03       Impact factor: 6.038

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.